# An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

> **NCT02760277** · PHASE2 · COMPLETED · sponsor: **ReveraGen BioPharma, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** Vamorolone 0.25 mg/day/day
- **DRUG:** Vamorolone 0.75 mg/day/day
- **DRUG:** Vamorolone 2.0 mg/day/day
- **DRUG:** Vamorolone 6.0 mg/day/day

## Key facts

- **NCT ID:** NCT02760277
- **Lead sponsor:** ReveraGen BioPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-28
- **Primary completion:** 2018-04-26
- **Final completion:** 2018-04-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02760277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02760277, "An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02760277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*